Lenaster

Hydrocortisone Sodium Phosphate, the active ingredient in Lenaster, is a corticosteroid presented as a sterile ophthalmic solution for ocular use. It reduces inflammation in the eye and is employed in the management of postoperative inflammation, allergic conjunctivitis, and other inflammatory ocular conditions.

GNH USA supplies Lenaster as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Lenaster (hydrocortisone sodium phosphate) is used to treat inflammatory conditions of the eye.

Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery. Allergic conjunctivitis: alleviates itching, tearing and hyperemia caused by allergens. Anterior uveitis: suppresses intra‑ocular inflammation and prevents tissue damage. Corneal inflammation (keratitis): diminishes edema and promotes healing of the corneal surface.

Common Side Effects: - Transient ocular irritation or burning sensation. - Increased intra‑ocular pressure. - Blurred vision. - Tearing or watery eyes. - Mild conjunctival hyperemia. - Foreign‑body sensation.

Serious or Rare Side Effects: - Secondary ocular infection. - Cataract formation with prolonged use. - Glaucoma due to sustained pressure rise. - Delayed wound healing after surgery. - Severe allergic reaction (e.g., angio‑edema). - Corneal ulceration or perforation.

Before initiating therapy, consider the following precautions: - Monitor intra‑ocular pressure: check IOP regularly during treatment. - Assess for active ocular infection: avoid use if infection is present. - Use the lowest effective duration: limit exposure to reduce risk of cataract or glaucoma. - Caution in patients with known steroid sensitivity: watch for hypersensitivity reactions. - Avoid concurrent use of other potent ocular steroids unless directed. - Store at ambient temperature: keep below 25°C, in the original container, protected from moisture and light.

Hydrocortisone sodium phosphate may interact with other ophthalmic agents.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Anticholinergic eye drops: may diminish anti‑inflammatory efficacy. - Monoamine oxidase inhibitors: rare risk of hypertensive response.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: increased risk of corneal toxicity. - Topical antibiotics: possible reduction in antimicrobial activity; monitor infection control.